Expression of TNF-α and CD44 is implicated in poor prognosis, cancer cell invasion, metastasis and resistance to the sunitinib treatment in clear cell renal cell carcinomas

International Journal of Cancer

Volumn 136, Issue 7, 2015, Pages 1504-1514

  Mikami, Shuji ^a   Mizuno, Ryuichi ^b   Kosaka, Takeo ^b   Saya, Hideyuki ^c   Oya, Mototsugu ^b   Okada, Yasunori ^b  

^a KEIO UNIVERSITY HOSPITAL   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KEIO UNIVERSITY   (Japan)

Author keywords

CD44; Epithelial mesenchymal transition; MMP; Renal cell carcinoma; TNF

Indexed keywords

GELATINASE B; HERMES ANTIGEN; MESSENGER RNA; NERVE CELL ADHESION MOLECULE; SUNITINIB; TUMOR NECROSIS FACTOR ALPHA; UVOMORULIN; ANTINEOPLASTIC AGENT; CADHERIN; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; CD44 GENE; CELL MIGRATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; DOWN REGULATION; DRUG EFFECT; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; PRIMARY TUMOR; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; TNF ALPHA GENE; TREATMENT OUTCOME; TUMOR GENE; TUMOR INVASION; UPREGULATION; CARCINOMA, RENAL CELL; CELL HYPOXIA; CELL MOTION; DRUG RESISTANCE; GENETICS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; METABOLISM; METASTASIS; MORTALITY; PATHOLOGY; PROGNOSIS;

ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; CADHERINS; CARCINOMA, RENAL CELL; CELL HYPOXIA; CELL MOVEMENT; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLES; KIDNEY NEOPLASMS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PYRROLES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84920952645     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29137     Document Type: Article

References (27)

1. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
2. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009;9:361-71.
3. Wu S, Boyer CM, Whitaker RS, et al. Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. Cancer Res 1993;53:1939-44.
4. Chuang MJ, Sun KH, Tang SJ, et al. Tumor-derived tumor necrosis factor-alpha promotes progression and epithelial-mesenchymal transition in renal cell carcinoma cells. Cancer Sci 2008;99:905-13.
5. Bhat-Nakshatri P, Appaiah H, Ballas C, et al. SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD441/CD24- phenotype. BMC Cancer 2010;10:411.
6. Muthukumaran N, Miletti-Gonzalez KE, Ravindranath AK, et al. Tumor necrosis factor-alpha differentially modulates CD44 expression in ovarian cancer cells. Mol Cancer Res 2006;4:511-20.
7. Zoller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 2011;11:254-67.
8. Harrison ML, Obermueller E, Maisey NR, et al. Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol 2007;25:4542-9.
9. Moldawer NP, Figlin R. Renal cell carcinoma: the translation of molecular biology into new treatments, new patient outcomes, and nursing implications. Oncol Nurs Forum 2008;35:699-708.
10. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90.
11. Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 2009;10:992-1000.
12. Griffioen AW, Mans LA, de Graaf AM, et al. Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. Clin Cancer Res 2012;18:3961-71.
13. Greene FL BC, Fleming ID, et al. Kidney. In: Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M, eds. AJCC cancer staging handbook: TNM classification of malignant tumors, 6th edn. NY: Springer, 2002. 323-8.
14. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6:655-63.
15. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
16. Mikami S, Katsube K, Oya M, et al. Expression of Snail and Slug in renal cell carcinoma: E-cadherin repressor Snail is associated with cancer invasion and prognosis. Lab Invest 2011;91:1443-58.
17. Shinojima T, Oya M, Takayanagi A, et al. Renal cancer cells lacking hypoxia inducible factor (HIF)21alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha. Carcinogenesis 2007;28:529-36.
18. Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002;168:2395-400.
19. Szlosarek P, Charles KA, Balkwill FR. Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer 2006;42:745-50.
20. Perez-Gracia JL, Prior C, Guillen-Grima F, et al. Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array. Br J Cancer 2009;101:1876-83.
21. Wiedmann MW, Mossner J, Baerwald C, et al. TNF alpha inhibition as treatment modality for certain rheumatologic and gastrointestinal diseases. Endocr Metab Immune Disord Drug Targets 2009;9:295-314.
22. Tamada M, Nagano O, Tateyama S, et al. Modulation of glucose metabolism by CD44 contributes to antioxidant status and drug resistance in cancer cells. Cancer Res 2012;72:1438-48.
23. Peng T, Zhang T, Lu X, et al. JNK1/c-fos inhibits cardiomyocyte TNF-alpha expression via a negative crosstalk with ERK and p38 MAPK in endotoxaemia. Cardiovasc Res 2009;81:733-41.
24. Lopez-Ilasaca M, Li W, Uren A, et al. Requirement of phosphatidylinositol-3 kinase for activation of JNK/SAPKs by PDGF. Biochem Biophys Res Commun 1997;232:273-7.
25. Reiterer G, Bunaciu RP, Smith JL, et al. Inhibiting the platelet derived growth factor receptor increases signs of retinoic acid syndrome in myeloid differentiated HL-60 cells. FEBS Lett 2008;582:2508-14.
26. Krishnamachary B, Penet MF, Nimmagadda S, et al. Hypoxia regulates CD44 and its variant isoforms through HIF-1alpha in triple negative breast cancer. PLoS One 2012;7:e44078.
27. Yu X, Deng L, Wang D, et al. Mechanism of TNF-alpha autocrine effects in hypoxic cardiomyocytes: initiated by hypoxia inducible factor 1alpha, presented by exosomes. J Mol Cell Cardiol 2012;53:848-57.